Skip to main content

Table 1 Patient and procedure characteristics

From: Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study

  N = 4,154* %
Female 1,127 27.1
Age group (years)   
<60 1,659 39.9
60-70 1,316 31.7
70+ 1,179 28.4
Medication use†   
Clopidogrel 3,931 94.6
Proton pump inhibitors 955 23.0
Aspirin 3,718 89.5
Vitamin K antagonists 301 7.2
Nonselective NSAIDs 509 12.3
COX-2 inhibitors 388 9.3
Oral glucocorticoids 309 7.4
Calcium channel blockers 1,153 27.8
Statins 3,606 86.8
Comorbidities‡   
Diabetes 586 14.1
Hypertension 178 4.3
Year of study entry   
2003 847 20.4
2004 1,836 44.2
2005 1,471 35.4
PCI Indication   
STEMI 844 20.3
UAP/NSTEMI 1,277 30.7
SAP 1,902 45.8
Other 131 3.2
Number of treated arteries§   
1 2,877 69.3
2 1,057 25.4
3 212 5.1
Number of Stents§   
1 3,301 79.5
2 631 15.2
3+ 208 5.0
Lesion Type§║   
A 898 21.6
B 2,165 52.1
C 1,091 26.3
  1. *Drug-eluting stents only (n = 3,548) and combination of drug-eluting stents and bare metal stents (n = 606).
  2. †Any prescription redemption during follow up.
  3. ‡Registered between 1977 and the index PCI date.
  4. §Data were not available on number of treated arteries for 112 patients, on the number of stents for 62 patients, and on lesion type for 6 patients.
  5. ║Lesion classification: A = non-complicated, length <10 mm; B = irregular, length 10–20 mm; C = irregular, side branch, 90 degrees, chronic occlusion, length 20 mm.
  6. Abbreviations: COX cyclooxygenase, NSAIDs nonsteroidal anti-inflammatory drugs, PCI percutaneous coronary intervention, STEMI ST-segment elevation myocardial infarction, SAP stable angina pectoris, UAP unstable angina pectoris, NSTEMI non-ST-segment elevation myocardial infarction.